Cargando…

JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients

Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonek, Robert, Guenter, Wojciech, Jałowiński, Robert, Karbicka, Anna, Litwin, Anna, Maciejowski, Maciej, Zajdel, Radosław, Petit, Veronique, Rejdak, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759948/
https://www.ncbi.nlm.nih.gov/pubmed/33261210
http://dx.doi.org/10.3390/jcm9123867
_version_ 1783627217304027136
author Bonek, Robert
Guenter, Wojciech
Jałowiński, Robert
Karbicka, Anna
Litwin, Anna
Maciejowski, Maciej
Zajdel, Radosław
Petit, Veronique
Rejdak, Konrad
author_facet Bonek, Robert
Guenter, Wojciech
Jałowiński, Robert
Karbicka, Anna
Litwin, Anna
Maciejowski, Maciej
Zajdel, Radosław
Petit, Veronique
Rejdak, Konrad
author_sort Bonek, Robert
collection PubMed
description Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-naïve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of >1.5. The seroprevalence was shown to increase along with the patient’s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-naïve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level.
format Online
Article
Text
id pubmed-7759948
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77599482020-12-26 JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients Bonek, Robert Guenter, Wojciech Jałowiński, Robert Karbicka, Anna Litwin, Anna Maciejowski, Maciej Zajdel, Radosław Petit, Veronique Rejdak, Konrad J Clin Med Article Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-naïve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of >1.5. The seroprevalence was shown to increase along with the patient’s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-naïve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level. MDPI 2020-11-27 /pmc/articles/PMC7759948/ /pubmed/33261210 http://dx.doi.org/10.3390/jcm9123867 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bonek, Robert
Guenter, Wojciech
Jałowiński, Robert
Karbicka, Anna
Litwin, Anna
Maciejowski, Maciej
Zajdel, Radosław
Petit, Veronique
Rejdak, Konrad
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title_full JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title_fullStr JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title_full_unstemmed JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title_short JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients
title_sort jc virus seroprevalence and jcvab index in polish multiple sclerosis treatment-naïve patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759948/
https://www.ncbi.nlm.nih.gov/pubmed/33261210
http://dx.doi.org/10.3390/jcm9123867
work_keys_str_mv AT bonekrobert jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT guenterwojciech jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT jałowinskirobert jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT karbickaanna jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT litwinanna jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT maciejowskimaciej jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT zajdelradosław jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT petitveronique jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients
AT rejdakkonrad jcvirusseroprevalenceandjcvabindexinpolishmultiplesclerosistreatmentnaivepatients